Oregovomab

Identification

Generic Name
Oregovomab
DrugBank Accession Number
DB04964
Background

Oregovomab is a murine monoclonal antibody that attaches to the tumor-associated antigen CA125.

Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Protein Structure
Db04964
Protein Chemical Formula
Not Available
Protein Average Weight
Not Available
Sequences
Not Available
Synonyms
  • Monoclonal antibody B43.13
  • Oregovamab
  • Oregovomab
External IDs
  • B 4313
  • MAb-B 4313
  • MAb-B43.13

Pharmacology

Indication

Investigated for use/treatment in ovarian cancer.

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics

Oregovomab is well tolerated and induces multiple antigen-specific immune responses, maintained during concomitant chemotherapy. A significant survival benefit has been observed in patients mounting a T-cell response to CA125 and/or autologous tumor. Vaccination with oregovomab may stimulate a host cytotoxic immune response against tumor cells that express CA125.

Mechanism of action

Oregovomab targets the circulating tumour-associated antigen CA 125, which is shed from the surface of human ovarian cancer cells; the antibodies induce broad cellular and humoral immune responses against CA 125 via complex formation. Unlike free CA 125, CA 125-oregovomab complexes can prime dendritic cells, leading to downstream activation of T cells.

TargetActionsOrganism
UMucin-16Not AvailableHumans
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Oregovomab.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Oregovomab.
AducanumabThe risk or severity of adverse effects can be increased when Oregovomab is combined with Aducanumab.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Oregovomab.
AlirocumabThe risk or severity of adverse effects can be increased when Oregovomab is combined with Alirocumab.
AmivantamabThe risk or severity of adverse effects can be increased when Oregovomab is combined with Amivantamab.
AnsuvimabThe risk or severity of adverse effects can be increased when Oregovomab is combined with Ansuvimab.
Anthrax immune globulin humanThe risk or severity of adverse effects can be increased when Oregovomab is combined with Anthrax immune globulin human.
Antilymphocyte immunoglobulin (horse)The risk or severity of adverse effects can be increased when Oregovomab is combined with Antilymphocyte immunoglobulin (horse).
Antithymocyte immunoglobulin (rabbit)The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Oregovomab.
Interactions
Improve patient outcomes
Build effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.
Learn more
Food Interactions
Not Available

Products

Products
Comprehensive & structured drug product info
From application numbers to product codes, connect different identifiers through our commercial datasets.
Learn more
Easily connect various identifiers back to our datasets
Learn more
International/Other Brands
OvaRex

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available
Affected organisms
  • Humans and other mammals

Chemical Identifiers

UNII
HX101E7L6S
CAS number
213327-37-8

References

General References
  1. Berek JS: Immunotherapy of ovarian cancer with antibodies: a focus on oregovomab. Expert Opin Biol Ther. 2004 Jul;4(7):1159-65. [Article]
  2. Gordon AN, Schultes BC, Gallion H, Edwards R, Whiteside TL, Cermak JM, Nicodemus CF: CA125- and tumor-specific T-cell responses correlate with prolonged survival in oregovomab-treated recurrent ovarian cancer patients. Gynecol Oncol. 2004 Aug;94(2):340-51. [Article]
  3. Ehlen TG, Hoskins PJ, Miller D, Whiteside TL, Nicodemus CF, Schultes BC, Swenerton KD: A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer. Int J Gynecol Cancer. 2005 Nov-Dec;15(6):1023-34. [Article]
  4. Authors unspecified: Oregovomab: anti-CA-125 monoclonal antibody B43.13--AltaRex, B43.13, MAb B43.13, monoclonal antibody B43.13. Drugs R D. 2006;7(6):379-83. [Article]
PubChem Substance
347909863
Wikipedia
Oregovomab

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3RecruitingTreatmentAbdominal wall neoplasm / Carcinoma, Ovarian Epithelial / Fallopian Tube Adenocarcinoma / Fallopian Tube Neoplasms / Fallopian Tube Serous Adenocarcinoma / Malignant Peritoneal Neoplasm / Neoplasms, Ovarian / Ovarian Cancer / Ovarian Serous Adenocarcinoma / Primary Peritoneal Cancer1
3TerminatedTreatmentOvarian Cancer1
2CompletedTreatmentAdenocarcinoma of the Pancreas / Resectable Pancreatic Carcinoma / Stage I Pancreatic Cancer / Stage IA Pancreatic Cancer / Stage IB Pancreatic Cancer / Stage II Pancreatic Cancer / Stage IIA Pancreatic Cancer / Stage IIB Pancreatic Cancer / Stage III Pancreatic Cancer1
2CompletedTreatmentNeoplasms, Ovarian1
2TerminatedTreatmentNeoplasms, Ovarian1
2TerminatedTreatmentOvarian Cancer1
2Unknown StatusTreatmentFallopian Tube Cancer / Ovarian Cancer / Primary Peritoneal Cavity Cancer2
1TerminatedTreatmentAdvanced Ovarian Cancer / Neoplasms, Ovarian / Ovarian Cancer / Ovarian Cancer Stage III / Recurrent Ovarian Cancer1
1, 2Active Not RecruitingTreatmentOvarian Epithelial Cancer1
1, 2TerminatedTreatmentNeoplasms, Ovarian1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Liquid
Experimental Properties
Not Available

Targets

Drugtargets
Accelerate your drug discovery research
with our fully connected ADMET & drug target dataset.
Learn more
Accelerate your drug discovery research with our ADMET & drug target dataset
Learn more
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Not Available
Specific Function
Thought to provide a protective, lubricating barrier against particles and infectious agents at mucosal surfaces.
Gene Name
MUC16
Uniprot ID
Q8WXI7
Uniprot Name
Mucin-16
Molecular Weight
1519158.08 Da
References
  1. Berek JS: Immunotherapy of ovarian cancer with antibodies: a focus on oregovomab. Expert Opin Biol Ther. 2004 Jul;4(7):1159-65. [Article]
  2. Authors unspecified: Oregovomab: anti-CA-125 monoclonal antibody B43.13--AltaRex, B43.13, MAb B43.13, monoclonal antibody B43.13. Drugs R D. 2006;7(6):379-83. [Article]

Drug created on October 21, 2007 22:23 / Updated on February 21, 2021 18:51